ScholarLens Back to search
2015•Unpublished venueRequires access

Myeloproliferative neoplasms:ten years after the discovery of JAK2 V617F gene mutation

Tian Ding

Open publisher page 0 citations

Abstract

This article focuses on the rapidly evolving understanding of the molecular pathogenetic mechanisms of the bcr-abl-negative myeloproliferative neoplasms (MPN) [myeloproliferative disorders (MPD)], such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). The amplify therapies were reviewed and IFN-α is an effective agent for these MPN (MPD). Also, the article emphasize once again avoidance MPN and select MPD for such chinese patients. Key words: Myeloproliferative neoplasms, MPN; Myeloproliferative disorders, MPD; JAK2 V617F gene mutation; Interferon-alpha

About this research paper

What this paper is about

This article focuses on the rapidly evolving understanding of the molecular pathogenetic mechanisms of the bcr-abl-negative myeloproliferative neoplasms (MPN) [myeloproliferative disorders (MPD)], such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). The amplify therapies were reviewed and IFN-α is an effective agent for these MPN (MPD). Also, the article emphasize once again avoidance MPN and select MPD for such chinese patients. Key words: Myeloproliferative neoplasms, MPN; Myeloproliferative disorders, MPD; JAK2 V617F gene mutation; Interferon-alpha

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This article focuses on the rapidly evolving understanding of the molecular pathogenetic mechanisms of the bcr-abl-negative myeloproliferative neoplasms (MPN) [myeloproliferative disorders (MPD)], such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). The amplify therapies were reviewed and IFN-α is an effective agent for these MPN (MPD). Also, the article emphasize once again avoidance MPN and select MPD for such chinese patients. Key words: Myeloproliferative neoplasms, MPN; Myeloproliferative disorders, MPD; JAK2 V617F gene mutation; Interferon-alpha

Key concepts: Essential thrombocythemia, Polycythemia vera, Myelofibrosis, JAK2 V617F, Myeloproliferative Disorders, Myeloproliferative neoplasm, Mutation, Gene mutation

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Myeloproliferative neoplasms:ten years after the discovery of JAK2 V617F gene mutation — Research Paper | ScholarLens